← Leaderboards
Candice D Fike
Wake Forest University Health Sciences
$5,581,838
Attributed
$5,581,838
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $561.2K · FY2006–20$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$5,581,838 · 4
By mechanism
R01$4,315,253 · 2
R34$705,388 · 1
R56$561,197 · 1
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Joshua Thomas Maxwell$1,942,500
- Allison W Miller$734,844
- Delrae M Eckman$342,805
- Debra I. Diz$10,478,847
- Patricia E Gallagher$2,799,578
Others in their field
Top investigators on “Pulmonary Hypertension”
- Marlene Rabinovitch · Stanford University$37,720,523
- Steven M Kawut · Columbia University Health Sciences$25,789,592
- Jason X.-J. Yuan · University Of California, San Diego$23,628,934
- Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru$23,127,355
- Mark Thomas Gladwin · Clinical Center$18,849,194
- Steven Herbert Abman · Johns Hopkins University$18,508,025
Research focus
Pulmonary HypertensionProductionChronicBlood VesselsNeonatal Pulmonary HypertensionCessation Of LifeSourceDesignHypoxiaInfantLungCardiacNewborn InfantFailure (Biologic Function)Pulmonary CirculationGenerationsEnzymesHeart DiseasesOralCitrullineComplicationArginineExposure ToPrevent
Grant awards (16)
Pharmacokinetics of oral L-citrulline in infants at high risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia$230,754
R34 · FY2020 · HL · contact PI
Pharmacokinetics of oral L-citrulline in infants at high risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia$231,758
R34 · FY2019 · HL · contact PI
Pharmacokinetics of oral L-citrulline in infants at high risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia$242,876
R34 · FY2018 · HL · contact PI
Chronic progressive hypoxia-induced pulmonary hypertension in newborns$532,766
R56 · FY2015 · HL · contact PI
Chronic progressive hypoxia-induced pulmonary hypertension in newborns$28,431
R56 · FY2015 · HL · contact PI
Chronic progressive hypoxia-induced pulmonary hypertension in newborns$525,533
R01 · FY2013 · HL · contact PI
Chronic progressive hypoxia-induced pulmonary hypertension in newborns$548,759
R01 · FY2012 · HL · contact PI
Chronic progressive hypoxia-induced pulmonary hypertension in newborns$553,113
R01 · FY2011 · HL · contact PI
Chronic progressive hypoxia-induced pulmonary hypertension in newborns$556,011
R01 · FY2010 · HL · contact PI
Prostanoids and Hypoxic Neonatal Pulmonary Hypertension$335,359
R01 · FY2009 · HL · contact PI
Prostanoids and Hypoxic Neonatal Pulmonary Hypertension$335,359
R01 · FY2008 · HL · contact PI
Prostanoids and Hypoxic Neonatal Pulmonary Hypertension$335,359
R01 · FY2007 · HL · contact PI
Prostanoids and Hypoxic Neonatal Pulmonary Hypertension$344,250
R01 · FY2006 · HL · contact PI
Prostanoids and hypoxic neonatal pulmonary hypertension$252,000
R01 · FY2004 · HL
Prostanoids and hypoxic neonatal pulmonary hypertension$252,000
R01 · FY2003 · HL
Prostanoids and hypoxic neonatal pulmonary hypertension$277,510
R01 · FY2002 · HL